(a)
(b)
(c)
(d)
Figure 2: (a, b) Prophylactic treatment with RvE1 starting with negative mice at day 21 and (c, d) therapeutic treatment with RvE1 starting after CIA development (all positive mice). Arthritis incidence and severity scores (0–2 per paw) of DBA1/J male mice treated with low (0.1 μg) and high dose (1ug) of RvE1, PBS, and 5 mg/kg anti-TNF and with a combination of 5 mg/kg anti-TNF plus 1 μg RvE1. Data were expressed as the of the mean (SEM). One-way ANOVA followed by Tukey’s posttest was used to assess the differences among the 4 groups. Student’s -test was used to access the differences between the 2 groups. Differences were considered significant at . Statistically significant difference from indicated groups (). Statistically significant difference from indicated groups ().